Literature DB >> 8852666

Dopa-responsive dystonia in British patients: new mutations of the GTP-cyclohydrolase I gene and evidence for genetic heterogeneity.

O Bandmann1, T G Nygaard, R Surtees, C D Marsden, N W Wood, A E Harding.   

Abstract

Dopa-responsive dystonia (DRD) was originally described in a series of Japanese patients, but is now increasingly recognized in other countries. Recently the GTP cyclohydrolase I (GTPCH) gene was isolated as the first causative gene for dopa-responsive dystonia (DRD). Mutations were identified in three Japanese families with autosomal dominantly inherited DRD and in one sporadic Japanese patient. Characterisation of the exon-intron boundaries of this gene has now allowed the analysis of mutations at the level of genomic DNA. Amplifying all six exons, we analyzed the GTPCH gene in nine British families with 33 affected family members and in three sporadic cases and found six new mutations. Only point mutations were found, causing a stop codon in one family and an amino acid change in highly conserved regions of the gene in a further four families and in one sporadic case. None of these mutations were detected more than once and none of the mutations previously described were found in our patients. No mutations were identified in four families and in two sporadic cases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8852666     DOI: 10.1093/hmg/5.3.403

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  20 in total

1.  Oral phenylalanine loading profiles in symptomatic and asymptomatic gene carriers with dopa-responsive dystonia due to dominantly inherited GTP cyclohydrolase deficiency.

Authors:  K Hyland; T G Nygaard; J M Trugman; K J Swoboda; L A Arnold; S P Sparagana
Journal:  J Inherit Metab Dis       Date:  1999-05       Impact factor: 4.982

2.  A splice mutation in the GTP cyclohydrolase I gene causes dopa-responsive dystonia by exon skipping.

Authors:  M Skrygan; B Bartholomé; L Bonafé; N Blau; K Bartholomé
Journal:  J Inherit Metab Dis       Date:  2001-06       Impact factor: 4.982

3.  Occurrence of GCH1 gene mutations in a group of Indian dystonia patients.

Authors:  Tufan Naiya; Amar K Misra; Arindam Biswas; Shyamal K Das; Kunal Ray; Jharna Ray
Journal:  J Neural Transm (Vienna)       Date:  2012-02-29       Impact factor: 3.575

4.  GTP cyclohydrolase I mutations in patients with dystonia responsive to anticholinergic drugs.

Authors:  P R Jarman; O Bandmann; C D Marsden; N W Wood
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-09       Impact factor: 10.154

Review 5.  Dopa-responsive dystonia, DRD-plus and DRD look-alike: a pragmatic review.

Authors:  Ajith Cherian; Naveen Kumar Paramasivan; K P Divya
Journal:  Acta Neurol Belg       Date:  2021-01-16       Impact factor: 2.396

6.  A novel point mutation in the GTP cyclohydrolase I gene in a Spanish family with hereditary progressive and dopa responsive dystonia.

Authors:  K Beyer; J I Lao-Villadóniga; B Vecino-Bilbao; R Cacabelos; R De la Fuente-Fernández
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-04       Impact factor: 10.154

7.  Genes and parkinsonism.

Authors:  N Wood
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-04       Impact factor: 10.154

8.  Urinary neopterin and phenylalanine loading test as tools for the biochemical diagnosis of segawa disease.

Authors:  Vincenzo Leuzzi; Claudia Carducci; Flavia Chiarotti; Daniela D'Agnano; Maria Teresa Giannini; Italo Antonozzi; Carla Carducci
Journal:  JIMD Rep       Date:  2012-04-18

9.  GCH1 heterozygous mutation identified by whole-exome sequencing as a treatable condition in a patient presenting with progressive spastic paraplegia.

Authors:  Zheng Fan; Robert Greenwood; Ana C G Felix; Yael Shiloh-Malawsky; Michael Tennison; Myra Roche; Kristy Crooks; Karen Weck; Kirk Wilhelmsen; Jonathan Berg; James Evans
Journal:  J Neurol       Date:  2014-02-08       Impact factor: 4.849

Review 10.  Tyrosine hydroxylase and Parkinson's disease.

Authors:  J Haavik; K Toska
Journal:  Mol Neurobiol       Date:  1998-06       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.